KN
Kiniksa Pharmaceuticals International, plc
KNSA · NASDAQ
$77.09 +0.97% (+$0.74)
1M +1.80%
Market Cap $6.13B
P/E Ratio 76.03x
Div. Yield -
ROE 13.65%
Bulios Fair Price
$71.53
7.2% downside
Current Price
$77.09
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KNSA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
12 /100
Expensive P/E 76.03x
EV/EBITDA 53.22x
P/S 7.29x
Growth
69 /100
Growing EPS growth 33.93%
Rev. growth 45.45%
FCF growth 64.56%
Profitability
78 /100
Strong Gross margin 54.49%
Net margin 9.59%
Op. margin 11.92%
Quality
64 /100
Average ROIC 9.71%
ROE 13.65%
ROA 9.00%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 3.90x
Net debt/EBITDA -1.49x
Stability
19 /100
Unstable Beta 0.09x
Rev. volatility 20.63%
EPS volatility 312.51%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KNSA
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Sanj K. Patel
Employees
366
Headquarters
London
Upcoming events
27 OCT
Earnings
Upcoming earnings report